Blog

NSCLC

Jan 14, 2025, 02:50

Phase 1b study of telisotuzumab vedotin in combination with osimertinib for NSCLC

Yakup Ergün Medical Oncologist at Antalya City Hospital shared on X:

“Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met–overexpressing, EGFR-mutated locally advanced/metastatic NSCLC after progression on prior osimertinib

ORR 50%
G3-4 Pulmonary embolism 8%!”

Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein–overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) after progression on prior osimertinib – Annals of Oncology

Authors: H. Horinouchi, B.C. Cho, D.R. Camidge, K. Goto, P. Tomasini, Y. Li, A. Vasilopoulos, P. Brunsdon, D. Hoffman, W. Shi, E. Bolotin, V. Blot, J. Goldman

Phase 1b study of telisotuzumab vedotin in combination with osimertinib for NSCLC

A. Vasilopoulos B.C. Cho cancer D. Hoffman D.R. Camidge E. Bolotin H. Horinouchi J. Goldman K. Goto NSCLC OncoDaily Oncology P. Brunsdon P. Tomasini V. Blot W. Shi Y. Li Yakup Ergün

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer

Black History Month 2025: Honoring Contributions to Oncology